Special Edition

Special Edition

Nilotinib Improves Prognosis in Elderly Patients with Ph+ ALL

For the difficult-to-treat elderly population (aged ≥55 years) with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL), combining age-adapted, low-intensity chemotherapy with nilotinib is...

Current Issue

September 2021 Volume 7 Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Block title